Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center
FRAMINGHAM, MA / ACCESS Newswire / July 30, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its collaboration partner, PeriNess Ltd. (“PeriNess”), has entered into a Clinical Study Agreement (the “Agreement”) to support an exploratory clinical study of DNase I in combination with anti-CD19 CAR T cells in patients with large B cell lymphoma.
Dr. Ron Ram, Professor of Medicine and Head of the Bone Marrow Transplantation Unit at the Tel Aviv Sourasky Medical Center (“Sourasky Center”), will act as the principal investigator of the study.
The primary objective of this study is to explore the safety and tolerability of DNase I in combination with anti-CD19 CAR T therapy in subjects with stable or progressive large B-cell lymphoma when DNase I is given in an adjuvant setting. Secondary objectives include efficacy to be evaluated by the measure of complete response rate post CAR T infusion, duration of response and overall survival. The study has the potential for a strong translational component with a complex assessment of biomarker response and analysis of anti-CD19 CAR T expansion and persistence.
“Our data suggests that the degradation of Neutrophil Extracellular Traps (NETs) by DNase I plays a crucial role in maintaining CAR T-cell function and preventing premature CAR T-cell exhaustion. Our preclinical studies conducted show that co-administration of DNase I with anti-CD19 CAR T cells significantly reduce tumor burden, delay tumor relapse and substantially prolong survival compared to the anti-CD19 CAR T cell monotherapy groups in various syngeneic and xenogeneic experimental models of lymphoma and leukemia,” stated Alexey Stepanov, PhD, Institute Investigator at the Scripps Research Institute, and a member of Xenetic’s Scientific Steering Committee.
“Progression of large B cell lymphoma (LBCL) is the major obstacle for the success of CAR T therapies, with approximately 40-60% of the patients relapsing in the first year, and 25-35% within 3 months after CAR T infusion, depending on the CAR T product used. While patients with partial or complete response before CAR T infusion have a 1-year progression free survival of 60-80%, those with stable or progressive disease at the time of CAR T infusion have a 1-year progression free survival of 20-30%. NETs facilitate several hallmarks of cancer biology at various stages, including progression, invasion, metastasis, immunosuppression, immune escape, and resistance to therapy. A high content of NETs in lymphoma tissue and blood of patients was associated with a negative outcome. The goal of this clinical study is to improve clinical response by administering DNase I to abrogate the negative effects of NETs on the performance of immune system and CAR T cells,” added Dr. Ram.
James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic concluded, “We are pleased with the continued progress of our DNase I program and the expansion of its development in another exploratory study to further evaluate its potential in various oncology indications. We look forward to garnering additional data to realize the full potential of DNase I.”
As previously announced, in December 2024, Xenetic entered into a Clinical Trial Services Agreement with PeriNess, under which PeriNess will lead in the regulatory approval, operational execution and management of potential exploratory, investigator-initiated studies of recombinant DNase I as an adjunctive treatment in patients with pancreatic carcinoma and other locally advanced or metastatic solid tumors receiving chemotherapy and immunotherapy in Israeli medical centers.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company’s DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is currently focused on advancing its systemic DNase I program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” “remain,” “focus”, “confidence in”, “potential”, and other words of similar meaning, including, but not limited to, all statements regarding expectations with respect to the Clinical Trial Services Agreement with PeriNess, including statements regarding the proposed investigator-initiated study under such agreement to support an exploratory clinical study of our systemic DNase I candidate in patients with large B-cell lymphoma and the expected objectives and goal of such study, and all statements regarding expectations for our DNase-base oncology platform, including statements regarding: our overall development strategy, the progress of our DNase I program, our expectations regarding further expansion of our body of clinical data, our focus on advancing innovative immune-oncology technologies addressing difficult to treat cancers, the DNase technology improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many cancers, and our focus on advancing our systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) the relevance of, or our ability to utilize, the data, if any, from any investigator-initiated exploratory study, (2) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements, including the Clinical Trial Services Agreement with PeriNess; (3) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (4) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (5) failure to realize the anticipated potential of the DNase technologies; (6) the ability of the Company to obtain funding and implement its business strategy; and (7) other risk factors as detailed from time to time in the Company’s reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues and geopolitical events, such as the conflicts in the Ukraine and in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation, and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.
Contact: JTC Team, LLC Jenene Thomas (908) 824-0775 xbio@jtcir.com
SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced that its drug candidate NV-387 is the weapon necessary for combatting growing cases of measles worldwide, especially in the industrialized world including, USA, Canada, UK, and European Union.
NV-387 is possibly the only drug candidate that has been shown to be effective and safe in animal model studies of Measles virus in humanized h-CD150+ knock-in mice, as reported previously by NanoViricides. NV-387 has completed a Phase I clinical trial with no reported adverse events, indicating excellent safety and tolerability in humans. The development of NV-387 as a treatment for Measles can be accelerated under the US FDA programs.
Measles is considered a rare orphan disease in the USA. As such, NV-387 for the treatment of Measles would qualify for an Orphan Drug Designation. Orphan drug designation qualifies sponsors for incentives including tax credits for qualified clinical trials, exemption from user fees, and potential seven years of market exclusivity after approval[1].
The Company also plans to explore a “Fast Track” designation for the NV-387 Measles indication. If granted, a drug approval can occur on the basis of a successful Phase II clinical trial without requiring a Phase III clinical trial, which significantly reduces the timeline to approval.
Measles has become an important disease of concern globally in the recent years for several reasons. Most importantly, Measles disease can wipe out the previously learned immunity of the patient against many infections, including from prior infections, and non-live virus vaccines, making the population vulnerable to viruses that were encountered previously. This is because Measles virus attacks the CD150-bearing immune cells that are responsible for memorizing the prior infections and mounting defenses against them later.
Measles is possibly the most communicable diseases, spreading through aerosol, that is known to humans. In patients, it produces severe morbidity with skin rash, pain, fatigue, and other syndromes. Rarely it can cause a brain disease. Measles mostly affects children.
There were a total of 1,319 confirmed measles cases reported in the USA as of July 22, breaking the most recent record of 1,274 cases in 2019. Hospitalization rates for measles in the USA are about 13%, and fatalities are rare, although in 2025 there were three deaths to date.
Canada is having a much worse Measles season than the USA, with more than 3,800 cases[2] to date in 2025.
A Measles holiday warning has been issued in the UK this year[3]. England itself had more than 3,000 cases of Measles in 2024.
In the European Region, 127,350 measles cases were reported for 2024, double the number of cases reported for 2023 and the highest number since 1997, according to an analysis by WHO and the United Nations Children’s Fund (UNICEF)[4] .
Worldwide, Measles cases continue to occur every year. Globally, there have been about 108,000 confirmed measles cases in 2025 to date, while in 2024 there were about 360,000 confirmed cases, according to the WHO[5].
A sustained measles vaccination rate of at least 95% is estimated to be required to maintain community immunity (“herd immunity”). Such a high rate is becoming increasingly difficult to achieve even in developed countries where access to vaccination is not an issue.
While growing vaccine hesitancy is considered an important reason for the fall in Measles vaccination rates, two other factors are of importance as well: (i) The overall population in the industrialized world, as well as in developing world, has increased frequency of immune dysfunction, obesity, and diabetes. The people with immune dysfunction or immune compromise are less likely to benefit from almost any standard vaccination as compared to healthy people and are likely to result in breakthrough infections. (ii) Additionally, the current vaccine for Measles is a live attenuated vaccine of the 1968 era, and the virus has evolved well past that, although so far the Measles virus strains continue to be susceptible to antibodies produced from the standard vaccine; this can change with continuing circulation of the virus in vaccinated persons and can result in a virus that can substantially defeat the vaccine[6].
Further, vaccine hesitancy itself is not irrational because the standard Measles vaccine is a live attenuated vaccine to be given to infants at early age; it is a virus infection that continues to remain in the subject, which is why it provides lifelong immunity. Measles infection itself also provides lifelong immunity that includes the current strains of the virus.
Thus, the Company projects continuing Measles cases worldwide, that require a drug to control the disease in the patient and its spread to others.
We believe NV-387 fills this important medical need. There is no approved drug for treatment of Measles at present.
NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.
The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.
FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.
[6]Measles happens to be a virus that does not readily escape vaccines and antibodies as other viruses do. This is because it lacks the “cloaking” feature on its cell-binding H-protein to hide the receptor-binding site. Other viruses use a cloaking feature and the cloak part mutates rapidly to evade vaccines and antibodies, allowing the virus to retain its ability to attack cells via the protected receptor-binding feature of its cell-binding protein.
SIOUX FALLS, SD / ACCESS Newswire / July 30, 2025 / The South Dakota Department of Health in partnership with Avel eCare, a national leader in innovative telemedicine solutions, is proud to introduce a new and uniquely impactful continuing education (CE) credit opportunity for emergency medical services professionals. Beginning August 25, EMS personnel who engage Avel for a telemedicine encounter will be eligible to earn CE credit – marking a first in virtual care.
This CE program has been approved by the South Dakota Board of Medical and Osteopathic Examiners. While the initial rollout is within South Dakota, Avel eCare intends to bring this innovative model to additional states and EMS systems across the country.
“This is more than a new offering, it’s a national first,” said Melissa Magstadt, Secretary of South Dakota Department of Health. “We’re not just improving care in the moment. We’re advancing the careers of EMS professionals, enhancing agency operations, and creating a full-circle support system that sets Avel apart.”
With this model, CE credit is earned in the field, not in a classroom. EMS teams continue to provide patient care while gaining access to expert guidance from Avel’s emergency physicians, paramedics, and nurses. A clinical debrief following the encounter reinforces decision-making and strengthens learning, making education an integrated part of every call.
While this program marks a major innovation, it also addresses a critical challenge in rural EMS: workforce turnover and training fatigue. EMTs and paramedics-many of them volunteers-juggle unpredictable call schedules, demanding clinical responsibilities, and state-mandated continuing education requirements. Traditionally, earning CE credits has meant additional time away from work or family, creating a strain on already overextended teams.
“Our board-certified physicians and experienced paramedics are delivering real-time clinical guidance and now, real-time professional development, all while helping providers stay hands-on with their patients” said Dr. Tyler Price, Medical Director at Avel eCare. “It validates what we’ve known all along – that our virtual interactions aren’t just helpful, they’re educational. We’re training and supporting EMS professionals in real time, with no disruption to the care they’re delivering.”
Through this real-time educational model, EMS personnel gain critical knowledge and confidence while in the field. Clinical support delivered in the back of the ambulance, followed by a brief debrief, reinforces learning in the context of real patient care.
“Avel’s model is not just about connecting clinicians through a screen,” concluded Doug Duskin, CEO of Avel eCare. “It’s about empowering communities with access to the highest level of medical care. And now, we’re extending that impact by offering accredited education, reinforcing our commitment to providers and patients alike.”
About Avel eCare Avel eCare is a national leader in technology-enabled clinical services delivered through telemedicine, offering provider-to-provider virtual care solutions that expand clinical capacity and improve outcomes across the healthcare industry. With more than 30 years of innovation, Avel’s board-certified clinicians partner with hospitals, clinics, long-term care facilities, schools, EMS agencies, and correctional health systems nationwide to bring high-quality care to patients when and where it’s needed most. Learn more at: www.avelecare.com
Global live streaming viewership grew 5% year-over-year to 9.1 billion hours watched during 2025 Q2, reflecting the highest quarterly level since 2021
FRISCO, TEXAS / ACCESS Newswire / July 30, 2025 / Stream Hatchet, the leading provider of data analytics for the live streaming and gaming ecosystem and wholly-owned subsidiary of GameSquare Holdings (NASDAQ:GAME), (“GameSquare”, or the “Company”), has released its Q2 2025 Live Streaming Trends Report. The report reveals key insights into the evolution of the global live streaming market across gaming, esports, and entertainment.
“The Q2 2025 report from Stream Hatchet underscores the continued growth of live streaming as a dominant force in media consumption,” said Justin Kenna, CEO of GameSquare. “These insights highlight how audiences are shifting toward interactive, creator-led content experiences that offer greater engagement than traditional formats.”
Key Insights from Stream Hatchet’s 2025 Q2 Report:
9.1 billion hours watched in 2025 Q2, reflecting the highest quarterly level since 2021
Live streaming viewership continues to grow, up 5% year-on-year, surpassing the 9 billion mark for the first time since 2021
YouTube Gaming recorded its highest ever quarterly viewership at 2.2 billion hours watched
Twitch’s market share continues to decline, down 4.6% in 2025 Q2 to 54%
YouTube Gaming holds onto just under a quarter of the market share
Kick continues to grow, with their market share up 5.5% to almost 11% of the streaming market
Despite 37% fewer tournaments compared to 2024 Q2, esports tournaments recorded a 6% increase in viewership to 729 million hours watched
Viewership was evenly split between co-streaming channels and official esports channels, highlighting audiences growing preference for creator-driven content
For more information on Stream Hatchet and insight into the esports and streaming markets, please visit their website at www.streamhatchet.com.
About GameSquare Holdings, Inc.
GameSquare (NASDAQ: GAME) is a cutting-edge media, entertainment, and technology company transforming how brands and publishers connect with Gen Z, Gen Alpha, and Millennial audiences. With a platform that spans award-winning creative services, advanced analytics, and FaZe Clan, one of the most iconic gaming organizations, we operate one of the largest gaming media networks in North America. Complementing our operating strategy, GameSquare operates a blockchain-native Ethereum treasury management program designed to generate onchain yield and enhance capital efficiency, reinforcing our commitment to building a dynamic, high-performing media company at the intersection of culture, technology, and next-generation financial innovation.
Stream Hatchet delivers real-time, actionable insights into the gaming and live-streaming ecosystem across 16 platforms. From performance benchmarking to campaign ROI and influencer intelligence, Stream Hatchet empowers game publishers, brands, agencies, and tournament organizers with the industry’s most granular data and reporting tools.
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the Company’s future performance, revenue, growth and profitability; and the performance of the live streaming market . These forward-looking statements are provided only to provide information currently available to us and are not intended to serve as and must not be relied on by any investor as, a guarantee, assurance or definitive statement of fact or probability. Forward-looking statements are necessarily based upon a number of estimates and assumptions which include, but are not limited to: the Company’s ability to grow their business and being able to execute on their business plans, the Company being able to complete and successfully integrate acquisitions, the Company being able to recognize and capitalize on opportunities and the Company continuing to attract qualified personnel to supports its development requirements. These assumptions, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: the Company’s ability to achieve its objectives, the Company successfully executing its growth strategy, the ability of the Company to obtain future financings or complete offerings on acceptable terms, failure to leverage the Company’s portfolio across entertainment and media platforms, dependence on the Company’s key personnel and general business, economic, competitive, political and social uncertainties. These risk factors are not intended to represent a complete list of the factors that could affect the Company which are discussed in the Company’s most recent MD&A. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. GameSquare assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
Corporate Contact Lou Schwartz, President Phone: (216) 464-6400 Email: ir@gamesquare.com
Investor Relations Andrew Berger Phone: (216) 464-6400 Email: ir@gamesquare.com
Media Relations Chelsey Northern / The Untold Phone: (254) 855-4028 Email: pr@gamesquare.com
With IRS tightening enforcement on dependents and tax credits, families face heightened scrutiny for mistakes on 2024 and 2025 returns
IRVINE, CA / ACCESS Newswire / July 30, 2025 / As the IRS ramps up enforcement in the wake of pandemic-era tax benefits and evolving digital filing tools, parents are being warned that mistakenly claiming the Child Tax Credit (CTC) – even unintentionally – could lead to audits, delayed refunds, or serious financial penalties.
Clear Start Tax, a leading tax resolution firm, is alerting taxpayers to a growing trend in IRS investigations centered around ineligible or duplicate child-related tax credit claims. With billions in credits distributed over the past few years and ongoing pressure to recover erroneous payments, experts say families should be extra cautious when preparing their tax returns – particularly when multiple households or caregivers are involved.
“The Child Tax Credit helped millions of families, but it also opened the door for confusion,” said a spokesperson for Clear Start Tax. “We’re seeing more cases where two parents each claimed the same child, or where someone claimed a dependent they’re no longer eligible for – often without realizing the full consequences.”
A Common Mistake, With Expensive Outcomes
The Child Tax Credit, which provides up to $2,000 per qualifying child, is meant to support low- and middle-income families. However, claiming the credit requires strict adherence to IRS eligibility rules, including proof of residency, relationship, and financial support. In 2025, the IRS is reportedly expanding its use of AI tools to detect inconsistencies and duplicate claims, triggering automated audits and refund delays.
For families navigating custody agreements, blended households, or informal caregiving situations, the rules can be murky – and mistakes are common.
“We’ve had clients come to us after receiving a CP75 letter from the IRS – a notice that flags their return for audit due to a claimed dependent,” said the Clear Start Tax spokesperson. “In some cases, their refund was frozen. In others, they were hit with repayment demands plus interest and penalties.”
According to IRS data, tens of thousands of families are flagged each year for dependent-related discrepancies, many stemming from unclear custody situations or outdated records. In more serious cases, repeated or fraudulent claims can even be referred for criminal investigation.
Prevention Over Penalties
While honest mistakes are not considered fraud, the IRS can still impose steep penalties if it deems a taxpayer was negligent or failed to correct known issues. In some cases, a taxpayer may be barred from claiming the credit for up to two years.
“Parents are often surprised to learn they can lose future eligibility just from one filing error,” said the Clear Start Tax spokesperson. “The best defense is proactive preparation and, if needed, professional guidance before filing.”
For those who’ve already received an IRS letter or notice related to the Child Tax Credit, Clear Start Tax advises acting quickly to avoid escalation. Responding with proper documentation within the deadline window is essential to protect refunds and avoid enforcement action.
By answering a few simple questions, taxpayers can find out if they’re eligible for the IRS Fresh Start Program and take the first step toward resolving their tax debt.
About Clear Start Tax
Clear Start Tax is a nationally recognized tax resolution firm helping individuals and families navigate complex IRS issues, from audits and debt to unfiled returns and penalties. With a focus on client advocacy and long-term financial solutions, the firm has helped thousands of taxpayers achieve relief and regain peace of mind.
Topical Ketamir-2 significantly reduced both acute and inflammatory pain behaviors in animals, demonstrating rapid onset, durable effect, and comparable efficacy to injected morphine across both pain phases
MIAMI, FLORIDA / ACCESS Newswire / July 30, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced new preclinical data showing that its topical Ketamir-2 cream delivered similar and consistent pain relief compared with injected morphine in a validated animal model of acute and inflammatory pain.
In the study, Ketamir-2 cream was applied topically to the affected area 30 minutes before pain was induced using the formalin model, a widely accepted preclinical method for evaluating both acute and inflammatory pain. In this model, a small amount of formalin (a dilute formaldehyde solution) is injected into the paw, producing two well-characterized phases of pain: an initial acute phase driven by direct nerve activation, followed by a prolonged inflammatory phase associated with central sensitization (a mechanism shared with neuropathic pain). Researchers monitored spontaneous pain-related behaviors-specifically paw licking and paw lifting-using AI-assisted video analysis of 5-minute slots over a 60-minute period.
Topical Ketamir-2 was effective as Injected morphine in both phases, nearly eliminating pain behaviors during the acute phase and maintaining a strong, durable effect throughout the inflammatory phase. These results indicate Ketamir-2’s potential to modulate both peripheral and central pain pathways with topical, localized delivery.
“These findings confirm Ketamir-2’s potential as a next-generation, non-opioid topical treatment for localized pain,” said Erez Aminov, Chairman and CEO of MIRA. “With our oral IND already cleared and a Phase 2a neuropathic pain trial expected to begin by year-end, this topical data meaningfully expands our clinical and commercial strategy. We’re advancing a dual-route platform that can target both systemic and localized pain conditions-offering optionality for patients and value for shareholders.”
Dual-Phase Pain Relief Without Systemic Burden
Unlike systemic analgesics, which circulate throughout the body and may cause unwanted side effects, Ketamir-2’s topical formulation is designed to provide direct, localized pain relief with minimal systemic exposure. Its performance across both acute and inflammatory pain phases supports a broad therapeutic profile-potentially applicable to conditions such as diabetic neuropathy, chemotherapy-induced peripheral neuropathy (CIPN), postherpetic neuralgia, and osteoarthritis.
“What’s remarkable is Ketamir-2’s ability to nearly abolish acute pain behavior while also suppressing inflammation-driven responses,” said Dr. Itzchak Angel, CSA at MIRA. “This dual-phase efficacy is rarely seen with topicals and strongly supports our rationale to continue advancing preclinical studies aimed at treating complex localized pain conditions.”
Addressing an $11.5 Billion U.S. Topical Pain Market
The U.S. topical pain relief market is projected to exceed $11.5 billion by 2025, driven by demand for safer, non-opioid, non-systemic options, according to a report by Research and Markets. Chronic pain affects more than 51 million adults in the U.S., and many of the most prevalent pain conditions-such as osteoarthritis and neuropathy-are localized in nature.
Ketamir-2’s topical formulation is designed to meet this need by offering:
Fast onset of action
Efficacy in both neurogenic and inflammatory pain
Minimal systemic absorption
Non-opioid, non-habit forming mechanism of action
Unlike many pain programs that pursue either systemic or localized delivery, MIRA is developing Ketamir-2 in both oral and topical forms. This dual-path approach may enable clinical evaluation across a broader spectrum of pain conditions-ranging from widespread neuropathic syndromes to localized inflammatory pain. If successful, this strategy could support differentiated product profiles and expand potential treatment opportunities.
A Scalable Non-Opioid Pain Platform
MIRA is currently conducting a Phase 1 clinical trial of oral Ketamir-2 in healthy volunteers. Following FDA clearance of its Investigational New Drug (IND) application, a Phase 2a clinical trial in neuropathic pain is expected to begin later this year in the USA.
The Company is also continuing preclinical development of the topical formulation to further characterize its pharmacological effects and support potential clinical advancement. Together, these efforts reflect a platform strategy designed to address high-burden pain conditions through both systemic and localized approaches.
“As we continue to execute on our clinical and regulatory milestones, we remain focused on unlocking the full value of the Ketamir-2 platform-either through internal advancement or strategic partnership,” added Aminov.
About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company’s pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline.
This press release and the statements of MIRA’s management related thereto contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA’s current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA’s control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA’s potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA’s programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at www.sec.gov and on MIRA’s website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
NEW YORK CITY, NY / ACCESS Newswire / July 30, 2025 / While AI tools and platforms are evolving faster than accounting professionals can adapt to them, it is still the people and processes within an organization that make them work. However, when individuals move on, this loss can create gaps within the organization, cracks leading to challenges in maintaining efficiency and continuity. To that end, alexion.ai today comes to market with an all-star executive team to guide the company towards its goal of keeping accounting decentralized, intelligent, and resilient.
Alexion acts as connective tissue across firm systems: normalizing unstructured data, reconciling fragmented context, and building AI-powered memory infrastructure. This foundation enables firm-specific agents to operate with trust, traceability, and nuance.
Alexion is not replacing accountants, they’re amplifying them. Preserving their logic. Codifying their judgment. And transforming individual expertise into shared intelligence that strengthens the entire firm.
In order to guide Alexion.ai’s path and ensure it delivers on all of the promises it makes and the technology it is building, the company has assembled an elite and diverse team of leaders that combine accounting, enterprise SaaS, design, and top-level AI backgrounds.
At the helm as alexion.ai’s CEO and Co-Founder is Lisa Griffith, who spent the last several years taking Laurel.AI to market and growing it to new heights as its head of accounting, go-to-market strategy, and partnerships. But her move to Alexion wasn’t about a product, it was about a pattern.
“I didn’t start with a product idea. I started with a pattern. After years inside firms, listening to partners, operators, and rising talent, I saw what was really eroding: not just efficiency, but continuity. The kind of deep, institutional judgment that lives in people, not platforms. And when those people leave, so does the logic.
Alexion is my response to that pattern. We’re not just building tools-we’re building memory. Infrastructure that captures how firms think, not just what they do. That codifies expertise into reusable logic. That enables AI agents to act with the same nuance and judgment as the professionals they support.
Because firms don’t lose value when someone leaves. They lose value when the way that person reasoned walks out the door with them.” – Lisa Griffith, CEO & Co-Founder, alexion.ai
For Guthrie Chen, Founder and Chief Visionary Officer of alexion.ai, the journey began with a simple idea: true financial understanding could break down nearly any barrier. His exploration brought him into collaboration with diverse experts, from mathematicians to entrepreneurs, where he saw how their specialized knowledge could be synthesized and automated to build a more accessible financial future for everyone.
“Our focus is on human creativity. AI has already come so far, and we want to build the brain, the ‘accountant’s brain,’ in a way that will evolve the world of accounting and tap into the data at our firms and build data you can trust,” said Chen. “We are making numbers real, as well as understanding each other’s languages and disciplines. You have to have that to build a proper product. Accounting can be very subjective; you have to make sure you aren’t forcing software on someone. As we build our brand and tech, it has to feel adaptive.”
Providing a crucial strategic and operational counterpart to Guthrie and Lisa’s vision is Matt McDonagh, Head of Strategy at Alexion. McDonagh brings a unique perspective forged on Wall Street as an investment banker before he pivoted to technology as an investor and a self-taught data engineer. He applies his expertise in using AI to refine strategy and build the operational backbone for Alexion’s growth.
The core challenge Alexion.ai addresses is data fragmentation. In most firms, institutional wisdom is locked in disconnected silos: scattered across white papers, trapped in internal memos, and separated by disparate accounting systems. This foundational problem became McDonagh’s focus after a pivotal meeting with Guthrie at a Family Office and Blockchain conference in Florida.
Impressed by Guthrie’s accounting background and technological approach, McDonagh was struck by its design philosophy: it was built by an accountant, for accountants. “That perspective was crucial,” McDonagh stated. “It was a tool born from the field. It made me realize the broader opportunity is unifying all of a firm’s existing, fragmented data. We saw AI agents fail because their data is unreliable. We saw an opportunity to transform the industry by aggregating this siloed intelligence. Our goal is to normalize it, creating a single source of truth that empowers everything else.”
Alexion.ai’s leadership team is rounded out by Head of Design Kris Andrews, Head of Product Minza Zahid, and Head of Finance Brian Sholley. Silicon Valley legends in Machine Learning and software engineering are working with the Alexion team to develop the technical roadmap to bring the power of AI to accounting. The company is also supported by an All-Star Advisory Board, including Gary L. Boomer, Rafael Casas, and Dr. Sean Stein Smith.
For more information, please reach out to Lisa Griffith.
TORONTO, ON / ACCESS Newswire / July 30, 2025 / Northern Superior Resources Inc. (“Northern Superior” or the “Company“) (TSXV:SUP)(OTCQB:NSUPF)(GR:D9M1) is pleased to announce additional results from its 20,000-metre expansion drilling campaign at the Philibert gold property, located just 9 km from IAMGOLD Corporation’s (“IAMGOLD“) Nelligan project and 60 km southwest of Chibougamau, Quebec (the “Philibert Project“: Northern Superior: 75%, SOQUEM: 25%).
Highlights Include: (Grades uncut; lengths are measured along the drill hole. See Table 1 for details.)
PB-25-490: 11.99 g/t Au over 9.1 metres, including 101.0 g/t Au over 1.0 metre, starting at 104.5 metres – Corsac Fox Hanging Wall Zone;
PB-25-502: 0.73 g/t Au over 46.8 metres, including 1.86 g/t Au over 9.5 metres, starting at 232.7 metres – Corsac Fox Hanging Wall Zone;
PB-25-504: 1.83 g/t Au over 18.8 metres, including 3.02 g/t Au over 10.6 metres, starting at 6.7 metres, and 1.75 g/t Au over 65.0 metres, including 3.92 g/t Au over 17.4 metres, starting at 94.5 metres – Arctic Fox Footwall Zone drilled parallel and down dip of mineralization (see Figure 3); and
PB-25-505: 1.29 g/t Au over 33.0 metres, including 5.71 g/t Au over 1.7 metres, starting at 9.0 metres – Arctic Fox Footwall Zone drilled parallel and down dip of mineralization.
“Today’s results focus on the middle and western extent of the conceptual pit, where we aimed to expand the Corsac Fox Hanging Wall zones. Hole PB-25-490 intersected very high grades near surface, outside of the current conceptual pit, and confirms the opportunity for significant resource expansion in this area. Moreover, drilling has filled in areas previously interpreted as non-mineralized due to sparse historical drilling,” said Simon Marcotte, President and Chief Executive Officer of Northern Superior.
“We are particularly encouraged by PB-25-504 (see Figure 3), which intersected mineralization right at the contact between the bedrock and overburden, just 4.7 metres vertically from surface-demonstrating the near-surface potential of this system. The continued success at the southeast pit, the recent deep high-grade hits, and now this new hanging wall mineralization, all underscore the potential to grow Philibert well beyond the current resource,” he added.
“PB-25-490 stands out with exceptional grade and width in an area where the pit shallows due to sparse historical drilling,” said Adree DeLazzer, Vice President of Exploration for Northern Superior. “Drillholes such as PB-25-502, which intersected 0.73 g/t over 46.5 metres, confirm strong mineralization continuity with meaningful width. These new intersections, located north of the Red Fox and Arctic Fox Footwall zones along the northern wall of the conceptual pit, continue to support our strategy of growing near-surface ounces along the 4-5 km Philibert trend. New structural and geochemical data are significantly enhancing our understanding of this large and evolving gold system,” she added.
Table 1: Significant Drillhole Intersections
DDH ID
From (m)
To (m)
Width (m)
Au Finale (g/t)
Comment
PB-25-490
104.5
113.6
9.1
11.99
Corsac Fox Hanging Wall
including
110.0
111.0
1.0
101.00
Corsac Fox Hanging Wall
PB-25-492
144.0
147.3
3.3
1.87
Corsac Fox Hanging Wall
including
144.8
145.3
0.5
4.84
Corsac Fox Hanging Wall
including
146.8
147.3
0.5
4.99
Corsac Fox Hanging Wall
PB-25-494
149.6
151.1
1.5
6.54
Corsac Fox Hanging Wall
and
166.3
172.0
5.7
1.15
Corsac Fox Hanging Wall
and
195.0
201.0
6.0
1.15
Corsac Fox Hanging Wall
PB-25-500
244.0
259.5
15.5
0.94
Corsac Fox Hanging Wall
including
244.0
245.5
1.5
7.67
Corsac Fox Hanging Wall
and
285.5
287.7
2.2
7.11
Corsac Fox Hanging Wall
including
285.5
286.7
1.2
10.68
Corsac Fox Hanging Wall
PB-25-502
232.7
279.5
46.8
0.73
Corsac Fox Hanging Wall
including
270.0
279.5
9.5
1.86
Corsac Fox Hanging Wall
PB-25-504*
6.7
25.5
18.8
1.83
Arctic Fox Footwall
Including*
12.4
23.0
10.6
3.02
Arctic Fox Footwall
and*
94.5
159.5
65.0
1.75
Arctic Fox Footwall
Including*
101.6
119.0
17.4
3.92
Arctic Fox Footwall
Including*
130.7
133.0
2.3
4.64
Arctic Fox Footwall
Including*
146.3
147.3
1.0
7.81
Arctic Fox Footwall
PB-25-505*
9.0
42.0
33.0
1.29
Arctic Fox Footwall
Including*
19.9
21.6
1.7
5.71
Arctic Fox Footwall
Grades have not been capped in the averaging and intervals are reported as drill thickness. True widths are estimated at 70% to 90%, except for drill holes marked with “*” which were drilled down dip and parallel to mineralization, with true widths estimated at 40% to 60%. Intersections are determined using 0.3 g/t Au cut-off and no more than 15 metres of consecutive dilution. If an intersection is 1 metre or less, dilution under 0.1 g/t Au may be used to determine a 2-metre intersection.
Figure 2: View looking northeast and dipping at 40 degrees – 200 metres width of Corsac Fox HW zone showing composite grade in Au g/t and highlights from press release labeled.
Figure 3: Picture of drill hole PB-25-504: 65.0 metres of 1.75 g/t Au starting at 94.5 metres including 17.4 metres of 3.92 g/t Au starting at 101.6 metres. Partial view of the intervale from 91.0 metres to 107.7 metres.
Drilling Results The current drill program tested the Corsac Fox Hanging Wall over a 750-metre strike length where historical drill density was low (see figures 1 and 2). Results from ten drill holes show that the Hanging Wall domains have a different style of mineralization to the well known footwall domain. The Hanging Wall domains are caracterized by a high-grade vein-style gold and broader envelopes near the northern wall of the conceptual pit (see tables 1 and 2). The hanging wall domains show a strong nugget effect compared to the footwall zones, and visible gold is frequently observed.
PB-25-490, located approximately 80 metres vertically from surface and 60 metres below the pit shell, intersected 11.99 g/t Au over 9.1 metres including 101.0 g/t Au over 1.0 metre. Another three drill holes tested the area where the conceptual pit shallows to surface over approximately 200 metres. PB-25-492, located 60 metres west of PB-25-490, returned 1.87 g/t Au over 3.3 metres. PB-25-489, situated 90 metres east of PB-25-490, intersected several narrow, higher-grade intervals, including 4.82 g/t Au over 1.5 metres, 2.17 g/t Au over 2.4 metres, and 4.15 g/t Au over 1.2 metres. PB-25-494, drilled 120 metres west of PB-25-490, returned multiple intervals from the hanging wall zones, including 6.54 g/t Au over 1.5 metres, 1.15 g/t Au over 5.7 metres, and 1.15 g/t Au over 6.0 metres.
Two drill holes were completed from the same setup approximately 600 metres west of PB-25-490, slightly off the main azimuth, to test the continuity of mineralization within the hanging wall zones in the western portion of the pit. PB-25-502 returned a broad intercept of 0.73 g/t Au over 46.8 metres, including a higher-grade interval of 1.86 g/t Au over 9.5 metres, highlighting strong potential for continuous, near-surface mineralization. PB-25-500 intersected 0.94 g/t Au over 15.5 metres, including 7.67 g/t Au over 1.5 metres, as well as additional higher-grade, narrower intervals such as 7.11 g/t Au over 2.2 metres and 10.68 g/t Au over 1.2 metres.
Two drill holes, PB-25-504 and PB-25-505, were completed to test the Arctic Fox Footwall zones down-dip of known mineralization, each drilled at different orientations to collect critical structural data and improve our geological understanding of the system. PB-25-504 intersected multiple broad and high-grade intervals including 18.8 metres grading 1.83 g/t Au from 6.7 metres, with a higher-grade core of 10.6 metres of 3.02 g/t Au. A second major zone returned 65.0 metres of1.75 g/t Au from 94.5 metres depth, including 17.4 metres of 3.92 g/t Au, with sub-intervals such as 4.0 metres of 5.37 g/t Au. PB-25-505 also intersected a broad mineralized zone of 33.0 metres of 1.29 g/t Aufrom9.0 metres, including a higher-grade section of 1.7 metres at 5.71 g/t Au. These holes confirm the presence of continuous and robust mineralization at the bedrock interface in the Arctic Fox Footwall and provide valuable data for refining the deposit’s structural model. Less historic work has been completed on the northern hanging wall domains, and the geological model and mineralization controls are currently being investigated using new structural core orientation and geochemical data to further refine the model.
The team is developing a follow-up drilling program to further investigate the higher grade near-surface mineralization as well as at depth to increase the ounces in the resource pit and potentially add an underground component to the resource.
Table 2: Drillhole Intersections for entire Press Release
DDH ID
From (m)
To (m)
Width (m)
Au Finale (g/t)
Comment
PB-25-485
75.0
78.2
3.2
0.39
Corsac Fox Hanging Wall
and
310.9
313.7
2.8
1.55
Corsac Fox Hanging Wall
PB-25-487
54.0
74.2
20.2
0.26
Corsac Fox Hanging Wall
including
60.0
64.5
4.5
0.40
Corsac Fox Hanging Wall
and
88.2
88.9
0.7
1.58
Corsac Fox Hanging Wall
PB-25-489
83.9
85.4
1.5
4.82
Corsac Fox Hanging Wall
and
103.6
106.6
3.0
1.53
Corsac Fox Hanging Wall
and
135.0
137.4
2.4
2.17
Corsac Fox Hanging Wall
including
135.0
135.9
0.9
5.00
Corsac Fox Hanging Wall
and
147.3
148.5
1.2
4.15
Corsac Fox Hanging Wall
and
157.8
159.3
1.5
1.97
Corsac Fox Hanging Wall
and
352.0
362.0
10.0
0.28
Arctic Fox Footwall
PB-25-490
49.1
56.0
6.9
0.57
Corsac Fox Hanging Wall
and
104.5
113.6
9.1
11.99
Corsac Fox Hanging Wall
including
110.0
111.0
1.0
101.00
Corsac Fox Hanging Wall
PB-25-492
144.0
147.3
3.3
1.87
Corsac Fox Hanging Wall
including
144.8
145.3
0.5
4.84
Corsac Fox Hanging Wall
including
146.8
147.3
0.5
4.99
Corsac Fox Hanging Wall
PB-25-494
135.1
141.5
6.4
0.40
Corsac Fox Hanging Wall
and
149.6
151.1
1.5
6.54
Corsac Fox Hanging Wall
and
166.3
172.0
5.7
1.15
Corsac Fox Hanging Wall
and
195.0
201.0
6.0
1.15
Corsac Fox Hanging Wall
and
386.5
391.6
5.1
0.32
Corsac Fox Hanging Wall
and
487.7
498.9
11.2
0.81
Corsac Fox Hanging Wall
PB-25-497
182.0
183.0
1.0
1.53
Corsac Fox Hanging Wall
and
207.0
210.0
3.0
0.77
Corsac Fox Hanging Wall
and
228.4
231.0
2.6
0.67
Corsac Fox Hanging Wall
including
230.0
230.5
0.5
2.86
Corsac Fox Hanging Wall
and
503.2
513.5
10.3
1.12
Arctic Fox Footwall
including
507.2
510.5
3.3
2.67
Arctic Fox Footwall
PB-25-499
204.0
205.5
1.5
0.40
Corsac Fox Hanging Wall
PB-25-500
232.0
233.5
1.5
2.88
Corsac Fox Hanging Wall
and
244.0
259.5
15.5
0.94
Corsac Fox Hanging Wall
including
244.0
245.5
1.5
7.67
Corsac Fox Hanging Wall
and
285.5
287.7
2.2
7.11
Corsac Fox Hanging Wall
including
285.5
286.7
1.2
10.68
Corsac Fox Hanging Wall
and
296.7
300.6
3.9
0.56
Corsac Fox Hanging Wall
and
338.3
339.8
1.5
0.47
Corsac Fox Hanging Wall
and
355.2
374.3
19.1
0.57
Corsac Fox Hanging Wall
and
399.8
401.3
1.5
1.74
Corsac Fox Hanging Wall
and
441.2
442.6
1.4
0.72
Arctic Fox Footwall
and
527.5
529.0
1.5
1.41
Arctic Fox Footwall
PB-25-502
232.7
279.5
46.8
0.73
Corsac Fox Hanging Wall
including
270.0
279.5
9.5
1.86
Corsac Fox Hanging Wall
and
335.0
355.0
20.0
0.46
Corsac Fox Hanging Wall
including
335.0
336.0
1.0
3.02
Corsac Fox Hanging Wall
and
402.5
416.0
13.5
0.75
Corsac Fox Hanging Wall
and
442.5
453.0
10.5
0.41
Corsac Fox Hanging Wall
PB-25-504
6.7
25.5
18.8
1.83
Arctic Fox Footwall
including
12.4
23.0
10.6
3.02
Arctic Fox Footwall
and
64.0
66.0
2.0
1.64
Arctic Fox Footwall
and
81.5
83.8
2.3
0.50
Arctic Fox Footwall
and
94.5
159.5
65.0
1.75
Arctic Fox Footwall
including
101.6
119.0
17.4
3.92
Arctic Fox Footwall
including
130.7
133.0
2.3
4.64
Arctic Fox Footwall
including
146.3
147.3
1.0
7.81
Arctic Fox Footwall
PB-25-505
9.0
42.0
33.0
1.29
Arctic Fox Footwall
including
19.9
21.6
1.7
5.71
Arctic Fox Footwall
and
66.0
74.9
8.9
0.75
Arctic Fox Footwall
Grades have not been capped in the averaging and intervals are reported as drill thickness. True widths are estimated at 70% to 90% except for drill holes marked with “*” which were drilled down dip and parallel to mineralization with true widths at 40% to 60%. Intersections are determined using a 0.3 g/t Au cut-off and no more than 10 metres of consecutive dilution. If an intersection is 1 metre or less, dilution under 0.1 g/t Au may be used to determine a 2-metre intersection.
The Chibougamau Gold Camp The Chibougamau Gold Camp is rapidly emerging as one of the world’s most sought-after gold destinations with several complementary gold resources reaching viable scale. In recent years, these critical assets were divided amongst five different companies. Today, largely due to Northern Superior’s acquisitions and corporate transactions,[1] ownership has been streamlined, with only IAMGOLD and Northern Superior holding these assets. The proximity of these deposits to each other makes them ideally suited to feed a single mill, and their consolidation enhances their viability, thereby increasing their value.
Below is a table showing the resources of the camp having been formalized to date.
Note: see NI-43-101 information below in notes 2, 3, 4, and 5.
Qualified Person (“QP”) The technical content and drilling results contained in this news release have been prepared in accordance with National Instrument 43-101 Standards of Disclosure for Mineral Projects (“NI 43-101“) and have been reviewed and approved by Ms. Melanie Pichon, P.Geo., Senior Geologist for Northern Superior. Ms. Pichon is a QP under the NI 43-101 and is not considered independent.
Northern Superior adheres to strict protocols following the NI 43-101 best practices when conducting exploration works. Sampling and assay results are monitored with strict QAQC protocols. Drilled core is processed and assayed in Northern Superior’s facilities in Chapais, Quebec. Core samples (half core) are transported to Agat Laboratory in Val d’Or.Samples are analyzed by fire assay with a 50-gram charge with an Atomic Absorption (AA) finish. Samples returning assay values over 10.0 grams are re-assayed with a gravimetric finish. QAQC consists of 4% of blank material, certified standards and duplicates inserted in the assay sequences by Northern Superior.
Corporate Matters On July 28, 2025, the Company entered an agreement with CanaCom Group (“CanaCom“), pursuant to which CanaCom agreed to provide digital content, marketing, and media distribution services to the Company. Pursuant to the terms of the agreement, such marketing services are to be provided over a 12-month period, commencing on August 1, 2025, for a monthly fee of C$7,500, plus applicable taxes. CanaCom is a full-service marketing agency based in Toronto, Ontario. CanaCom provides digital marketing awareness via advertising through its fully owned platform theDeepDive.ca, which includes both video and written content coverage of Canadian small-cap companies. CanaCom operates as an arm’s length service provider to the Company and is owned by Mr. Jordan Lutz.
About Northern Superior Resources Inc. Northern Superior is a gold exploration company focused on the Chibougamau Camp in Québec, Canada. The Company has consolidated the largest land package in the region, with total land holdings currently exceeding 68,000 hectares. The main properties include Philibert, Hazeur (adjacent to Philibert), Lac Surprise, Chevrier, Croteau, Monster Lake East, and Monster Lake West. Northern Superior also owns 56% of ONGold Resources Ltd. (TSXV:ONAU)(OTCQX:ONGRF) which is advancing promising exploration assets in Northern Ontario and Manitoba, including the district scale TPK Project and Monument Bay; Agnico Eagle Mines Limited owns 15% of ONGold Resources Ltd.
The Philibert Project is located 9 km from IAMGOLD Corporation’s Nelligan[2] Gold project. Philibert hosts a maiden 43-101 inferred resource of 48.46 Mt at 1.10 g/t Au for 7.88 Mt at 1.10 g/t Au for 1,708,800 ounces Au and an indicated resource of 278,900 ounces Au.[3] Northern Superior holds a majority stake of 75% in the Philibert Project, with the remaining 25% owned by SOQUEM, and retains an option to acquire the full 100% ownership of the project. Chevrier hosts an inferred mineral resource of 15.7 Mt at 1.30 g/t Au for 652,000 ounces Au (underground and open pit) and an indicated mineral resource of 6.4 Mt at 1.26 g/t Au for 260,000 ounces Au.[4] Croteau hosts an inferred mineral resource of 11.6 Mt at 1.7 g/t Au for 640,000 ounces Au.[5] Lac Surprise hosts the Falcon Zone Discovery, interpreted to be the western strike extension of IAMGOLD Corporation’s Nelligan Gold project.
Northern Superior is a reporting issuer in British Columbia, Alberta, Ontario and Québec, and trades on the TSXV under the symbol SUP and the OTCQB Venture Market under the symbol NSUPF. For further information, please refer to the Company’s website at www.nsuperior.com or the Company’s profile on SEDAR+ at www.sedarplus.ca.
About SOQUEM SOQUEM, a subsidiary of Investissement Québec, is dedicated to promoting the exploration, discovery, and development of mining properties in Québec. SOQUEM also contributes to maintaining strong local economies. Proud partner and ambassador for the development of Québec’s mineral wealth, SOQUEM relies on innovation, research, and strategic minerals to be well-positioned for the future.
Northern Superior Resources Inc. on Behalf of the Board of Directors Simon Marcotte, CFA, President and Chief Executive Officer
Contact Information Katrina Damouni Director – Corporate Development Tel: +44 7795 128583 (Mobile/WhatsApp) info@nsuperior.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Cautionary Note Regarding Forward-Looking Information This news release contains “forward-looking information” within the meaning of the applicable Canadian securities legislation that is based on expectations, estimates, projections and interpretations as at the date of this news release. The information in this news release that is not a historical fact may be “forward-looking information”. Any statement that involves discussions with respect to predictions, expectations, interpretations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “interpreted”, “management’s view”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information and are intended to identify forward-looking information. This forward-looking information is based on reasonable assumptions and estimates of the management of Northern Superior, at the time it was made, involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the companies to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Although the forward-looking information contained in this news release is based upon what management believes, or believed at the time, to be reasonable assumptions, the parties cannot assure shareholders and prospective purchasers of securities that actual results will be consistent with such forward-looking information, as there may be other factors that cause results not to be as anticipated, estimated or intended, and neither party nor any other person assumes responsibility for the accuracy and completeness of any such forward-looking information. Neither party undertakes, and assumes no obligation, to update or revise any such forward-looking statements or forward-looking information contained herein to reflect new events or circumstances, except as may be required by law.
[1] Including Northern Superior’s acquisitions of Genesis Metals Corp. and Royal Fox Gold Inc.
[2] “lAMGOLD Announces Significant Increase in Nelligan Ounces & Update of Global Mineral Reserves and Resources”;
IAMGOLD reports increase in mineral reserves and resources at existing assets, with increase in resources at Gosselin; IAMGOLD Corporation News Release dated February 15, 2024, October 23, 2024, and February 20, 2025. Note that the technical and scientific information disclosed from neighboring properties does not apply to any other properties of the area.
[3]Northern Superior announces 1,708,809 gold ounces in inferred category and 278,921 gold ounces in indicated category at 1.10 g/t in maiden NI 43-101 pit constrained resource estimate at Philibert; Northern Superior’s press release dated August 08, 2023.
[4] NI 43-101 Technical Report Mineral Resource Estimation for the Chevrier Main Deposit, Chevrier Project Chibougamau, Quebec, Canada, October 20, 2021, Prepared in accordance with NI 43-101 by Lions Gate Geological Consulting Inc. IOS Services Géoscientifiques Inc. for Northern Superior.
[5]Chalice Gold Mines Limited and Northern Superior Resources Inc. Technical Report on the Croteau Est Gold Project, Québec, September 2015, Prepared in accordance with NI 43-101 by Optiro Pty Ltd (“Optiro”) to Chalice Gold Mines Limited and Northern Superior.
Boost beer cave and heavy product sales with Planniq Strong®, high-capacity merchandising system from ImageWorks Display
WINSTON-SALEM, NC / ACCESS Newswire / July 30, 2025 / Retail merchandising leader ImageWorks Display® has made it easier than ever to boost beer cave and heavy product sales with its Planniq Strong® high-capacity merchandising system. Planniq Strong delivers one of the fixture industry’s highest weight capacities with 2,000-pounds-per-four-foot-sections to help convenience and grocery retailers stock and sell beer, beverages and bulky products with confidence.
ImageWorks CEO Justin Raney said Planniq Strong fixtures were designed to maximize in-store sales of heavy product in a format previously unavailable to convenience and grocery store retailers. “Conventional convenience store shelves and fixtures were never designed to handle the heaviest merchandise,” said Raney. “Increasingly though, that’s what shoppers are seeking. They want more beverage options, they’re interested in seasonal merchandise displayed outdoors, and they want to save time by buying heavy merchandise like pet food or automotive supplies in a more convenient retail setting.”
“ImageWorks has removed that limitation with our Planniq Strong system,” Raney adds. “Planniq Strong opens up a range of new revenue opportunities for retailers seeking to maximize beer cave, seasonal and heavy product sales. The system is durable enough to add capacity outdoors while also making beer cave and other indoor merchandise more accessible to shoppers.”
Planniq Strong fixtures build upon the foundational structures established by the ImageWorks Display collection of Planniq center store fixtures. The Planniq Strong system’s clean design and sleek black finish integrate into any retail environment, including those with the ImageWorks Xulta line of back bar displays. Planniq Strong fixtures are available in stock in 60″ or 72″ heights, and your choice of 24″, 36″ or 48″ center-to-center fixture widths.
Like other Planniq center store displays, the Planniq Strong line features your choice of flat wire or sheet metal shelving. The system’s post-free design offers a clear line of site for enhanced product visibility and accessibility. Corner kits are available, as well as optional wire and flip headers.
Raney notes that ImageWorks Display continues to innovate in beer cave and heavy product merchandising, with several new products in late-stage development. Like its existing Planniq and Xulta lines, the new ImageWorks offerings are designed to deliver a total store solution to create an elevated, cohesive environment that attracts customers and increases sales.
Since 1996, ImageWorks Display® has been creating both in-stock and custom retail display solutions within the merchandising industry. Considered a “total store solution” provider with unique expertise and offerings for whole-store integration, ImageWorks Display is known for its high-quality materials, performance engineering, innovative designs, and end-to-end customer service – service that places the client at the center of decision-making.
Their customer-centric business philosophy, along with their top-quality display products, have earned ImageWorks Display the privilege of being in many small-business and large-chain convenience stores throughout the U.S. Their back bar Xulta Impact® and Xulta Classic® products are the standard-setting solutions within the display industry.
Their center store gondola solution line includes Planniq Tech®, Planniq Core®, Planniq Strong, Planniq Lock®, Planniq Bev®, and Planniq Queue™. Both the Xulta back bar and Planniq center store product lines maximize dynamic retail environments with elevated and cohesive designs, resulting in increased sales and improved shopper experiences. Another area in which ImageWorks excels is the practical application of product pusher technology. Their pushers are known in the industry as the ones that never break. Strong product pushers and strong pusher tactics combine to help clients increase both sales and profitability.
Many clients choose to co-create custom solutions with the ImageWorks Display engineering and design teams. Clients see ImageWorks Display as an extension of their own merchandising team. This design collaboration encourages innovation and creativity, while resulting in highly effective display solutions that stand the test of time.
ImageWorks Display offers premium quality fixtures for a range of retail environments, along with lifetime product support, best-in-class supply chain management, and robust client service for every client partnership it enters. Nothing is more important than enduring relationships with loyal clients. This dedication is at the core of what drives their success. And it’s also what assures the success of their highly valued clients.
Contact: Anne M. Berg, President Vyway® Market & Brand Strategy anne@vyway.com | 651-271-1111
Reflection Family Interventions and The Family Recovery Foundation Launch Groundbreaking 24-Week Family Recovery Curriculum
PHOENIX, AZ / ACCESS Newswire / July 29, 2025 / What should you do when a loved one refuses help for addiction or mental illness? For families caught in the chaos of crisis, the traditional answer-“wait until they hit bottom”-has caused more harm than healing.
Reflection Family Interventions, a national leader in family intervention services, is proud to announce a groundbreaking partnership with The Family Recovery Foundation, a nonprofit dedicated to restoring families affected by behavioral health disorders. At the heart of this collaboration is a first-of-its-kind, 24-week intervention-specific family recovery curriculum, designed by Reflection exclusively for families navigating a loved one’s refusal of care.
“The most important question families can ask isn’t just ‘why won’t they get help?’-it’s ‘what is making a life of dysfunction feel safer than a life of recovery?’” said Andrew Engbring, Founder of Reflection Family Interventions and longtime board member of The Family Recovery Foundation. “We help families answer that question, heal their role in the cycle, and guide their loved one into recovery-even when they’re saying no.”
A New Standard of Care for Families in Crisis For decades, families have been left behind in the behavioral health system. Interventionists often offer only 2-3 days of support. Treatment centers give families basic psychoeducation and suggest attending Al-Anon. That approach fails to address the complex dynamics, trauma, and codependency that keep families stuck.
Reflection Family Interventions is redefining what true family-centered recovery looks like.
One Arizona family came to Reflection after their adult daughter had refused treatment for her fentanyl addiction multiple times. The family was heartbroken, divided, and unsure if she would survive. “They had tried everything-pleading, negotiating, even accepting partial efforts just to keep the peace,” said Engbring. “They were emotionally drained and walking on eggshells.”
Through Reflection’s 24-week family recovery program, the family finally stopped rescuing and started healing. They completed the curriculum together, learned to set unified boundaries, and several family members even began their own recovery journeys.
Within hours of the intervention, their daughter entered treatment-and for the first time, the entire family began to heal. Today, they are sober, united, and thriving-filled with laughter, love, and genuine peace. Most remarkably, the daughter herself left Reflection a heartfelt 5-star review, thanking the very team that intervened.
“It’s rare for the person in crisis to praise the intervention process,” said Andrew Engbring, “but when the whole family commits to change, the outcome speaks for itself.”
The Old Model vs. The Reflection Model:
Traditional Model
Reflection’s New Standard
2-3 day intervention
6-12 months of guided recovery
“Wait for bottom”
Engage the whole system now
Generic advice
Customized family curriculum
Focus on the individual
Treat the family as the client
Surface-level support
Trauma-informed, long-term coaching
The 24-Week Curriculum: A Pathway to Real Change
The newly launched curriculum-available in partnership with The Family Recovery Foundation-equips families with education, structure, and emotional tools to:
Understand why a loved one resists treatment
Stop enabling, rescuing, and walking on eggshells
Set boundaries rooted in love, not fear
Begin their own healing journey
Rebuild and reintegrate their loved one into a healthier family system
“Families are not just affected by addiction and mental illness-they are deeply entangled in it,” said Shahar Engbring, Co-Founder and Director of Admissions at Reflection. “Our process transforms that entanglement into empowerment. When the family gets well, the entire system begins to change.”
This model also includes professional interventionists, in-home psychiatric stabilization, post-treatment reintegration planning, and access to free or low-cost virtual support groups, coaching, and education through the Foundation.
“This partnership brings depth and structure to our mission,” said Paul Alexander, Founder of The Family Recovery Foundation. “Reflection’s curriculum fills a longstanding gap in the recovery field-families now have a step-by-step pathway to healing, instead of being left in the dark.”
This Comprehensive Model Includes:
Nationwide addiction and mental health intervention services
24-week intervention-specific family curriculum
Six-month family coaching and reintegration support
Faith-informed, trauma-sensitive support groups and resources
In-home psychiatric stabilization and care coordination
Setting a New Industry Standard Reflection Family Interventions and The Family Recovery Foundation believe this collaboration represents a long-overdue shift in how the recovery field supports families. By focusing on education, structure, and long-term healing, they hope to inspire change throughout the intervention and treatment landscape.
“Families are not an afterthought,” said Shahar Engbring. “They are the key to sustainable recovery. We hope this model sets a new standard of care throughout the industry.”
Call to Action Families in crisis, treatment professionals, and community organizations can learn more or request confidential support by visiting:
To access free family resources and enroll in nonprofit-based services, visit: https://tfrfoundation.org/
About Reflection Family Interventions Reflection Family Interventions is a family-owned, trauma-informed intervention and coaching company offering nationwide support to families affected by addiction and mental health disorders. Their comprehensive model includes crisis intervention, long-term coaching, in-home stabilization, and post-treatment reintegration.
About The Family Recovery Foundation The Family Recovery Foundation is a 501(c)(3) nonprofit providing education, coaching, and community-based support to families impacted by addiction and mental illness. Its mission is to restore families through compassion, faith, and practical guidance.
